| Fri, 21 Jul 2017 15:20:24: | With Viagra and Lyrica fading, analysts downgrade Pfizer due to mounting challenges
|
| Fri, 21 Jul 2017 14:40:18: | Cyndi Lauper showcases backstage psoriasis woes in Novartis' new Cosentyx spot
|
| Fri, 21 Jul 2017 14:16:18: | Merck’s Zostavax draws new litigation from patients alleging they contracted shingles
|
| Fri, 21 Jul 2017 13:25:58: | FiercePharmaAsia—Takeda’s workforce rejig and Velcade patent win, China’s insurance drug list
|
| Fri, 21 Jul 2017 12:50:05: | In internal memo, AstraZeneca chief Soriot reassures staffers as Teva rumors swirl
|
| Thu, 20 Jul 2017 15:26:41: | Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus
|
| Thu, 20 Jul 2017 15:25:45: | Discount helps NICE flip-flop on Teva's severe asthma contender, Cinqair
|
| Thu, 20 Jul 2017 15:24:19: | Canada pushed to take federal action against Purdue over OxyContin marketing
|
| Thu, 20 Jul 2017 14:41:09: | CSL launches Cinryze rival Haegarda despite Shire's best efforts—at a big discount, too
|
| Thu, 20 Jul 2017 13:13:51: | Merck's Keytruda speeds its I-O market-share grab as Bristol-Myers' Opdivo declines
|
| Thu, 20 Jul 2017 13:06:46: | Puma to price new cancer med Nerlynx at a higher-than-expected $10K per month: report
|
| Thu, 20 Jul 2017 12:22:59: | How did Johnson & Johnson beat back Remicade's biosim? Call it the art of the deal
|
| Wed, 19 Jul 2017 15:20:12: | Gilead gets its go-ahead for blockbuster hopeful Vosevi, but will 12-week dosing give it trouble?
|
| Wed, 19 Jul 2017 15:15:24: | Novartis CEO says shopping for bolt-ons is tough. Why? Creeping biotech deal prices
|
| Wed, 19 Jul 2017 14:19:32: | GlaxoSmithKline revamp to cost hundreds of U.K. manufacturing jobs
|
| Wed, 19 Jul 2017 14:19:29: | To win blockbuster spots on China's coverage list, Big Pharma offers big discounts
|
| Wed, 19 Jul 2017 13:55:36: | More states pour into generics price-fixing probe, suing Mylan, Teva and others
|
| Wed, 19 Jul 2017 13:46:37: | For Biogen's Spinraza launch, things are looking up on the coverage front: analyst
|
| Wed, 19 Jul 2017 12:40:25: | J&J's Invokana continues downward market-share spiral as Lilly, BI's Jardiance advances
|
| Wed, 19 Jul 2017 12:11:25: | Pharma's U.S. reputation is bad—and Trump may be to blame: survey
|
| Tue, 18 Jul 2017 18:46:00: | The flu vaccines are coming: GSK, Sanofi ship the first of more than 150M doses headed to U.S.
|
| Tue, 18 Jul 2017 16:55:49: | With eyes on Glaxo's Engerix-B vaccine, VBI takes hep B candidate into phase 3
|
| Tue, 18 Jul 2017 15:16:20: | Remicade is ready to fend off biosim No. 2, Johnson & Johnson executives say amid Q2 revenue miss
|
| Tue, 18 Jul 2017 14:15:23: | Novartis gets boost from an unexpected source—Alcon—as generic pricing sinks Sandoz sales
|
| Tue, 18 Jul 2017 14:13:58: | Takeda relocates hundreds of R&D, vaccine jobs and cuts 480 in sales: report
|
